Compare HSBC Holdings plc (HSBC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Travere Therapeutics Inc. Common Stock — how do they compare? HSBC Holdings plc trades at $94.47 (market cap $323.18B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: HSBC Holdings plc is far larger — about 66.2× Travere Therapeutics Inc. Common Stock's market cap, and HSBC Holdings plc pays a 3.95% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 37 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HSBC | TVTX | |
|---|---|---|
Market Cap | $323.18B | $4.88B |
Volume | 1,876,560 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $107.86 | $67.52 |
52-Week Low | $65.67 | $26.79 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $229.73B | $5.01B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $94.85, up 0.56% today, with a bearish technical signal from moving averages and ADX. The stock shows solid fundamentals with a P/E of 13.55, net income margin of 34.54%, and recent earnings beats in Q4 2025 and Q2 2026. Recent news highlights strategic expansions in TMT banking and India equity broking, alongside a planned CFO transition in 2027.
The outlook is mixed: valuation appears reasonable and profitability is strong, but technical indicators signal caution and analyst consensus leans Hold. Key risks include execution of growth initiatives and macroeconomic pressures. The stock offers income with a $0.50 dividend, but investors should weigh near-term technical weakness against long-term fundamental strength.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
